STATE OF THE ART
REGENERATIVE MEDICINE
STATE OF THE ART
REGENERATIVE MEDICINE
Your tissue, your cure
Your tissue, your cure
CuroTis is introducing, off-the-shelf, body-own tissue,
grown in the human body, and at the location where it is
needed
CuroTis’ platform technology is the next generation of
body-own regenerative medicine
It is set to redefine medicine with its proprietary
technology which (re)grows body-own tissue in the body
at the locations where it is needed
It is a user-friendly, cost-effective, off-the-shelf, and
scalable solution.
It is our strong belief that the (re)generation of new tissue becomes the treatment modality of choice for a
wide range of disease areas, injuries, and chronic conditions. This new therapeutic mode addresses unmet
needs across many medical fields, and replaces complex in-lab processes and use of artificial materials.
The core of the CuroTis’ platform technology is a
robust scaffold, the XS Graft system
Made of a biocompatible polymer with a defined
surface structure
It is shaped according to the size and function of the
required tissue
It is robust, has a long shelf life, and is stored and
transported at ambient conditions
A minimally invasive procedure creates the new tissue:
Step 1: the scaffold is implanted in an outpatient
procedure, requiring just a 2-3 cm incision
Step 2: the new tissue grows in just 4 weeks
Step 3: the scaffold is subsequently removed
The new tissue stays behind at location, ready for use
A strong tissue is formed comprising a collagen
matrix incorporating myofibroblasts
Resulting in a layer of
myofibroblasts that form a
collagen matrix
The immune cells respond with the
secretion of cytokines and induce
fibroblast to migrate into the
emerging tissue
The proteins provide an anchor
point for specific immune cells
Upon implantation of the device
the surface attracts selective
proteins
CuroTis’ regenerative platform technology
harnesses the body’s own processes to
(re)grown new tissue
0.0s
The technology to (re)grown human tissue in the human body has
vast number of applications. The focus for the first application is on
the unmet need of haemodialysis access
haemodialysis
neurology
facial
reconstruction
cardiovascular
urology
breast cancer
reconstruction
peripheral arterial
occlusive disease
ligaments
The XS Graft has been optimised to generate
body-own vascular tissue in the human body
A true life line for end stage haemodialysis
patients
The next vasculair applications in
development are peripheral arterial occlusive
disease and cardiovascular
Beyond the vascular field the investigation
into the application for breast cancer
reconstruction and facial reconstruction are
progressing towards clinical testing
First indications for neurological, urology and
ligament applications are promising and
preparing for preclinical testing
The XS GRAFT, a life line
End stage renal disease patient
require dialysis to replace the failed
kidney function
An access point is needed to connect
the patient blood system with the
dialysis equipment
A connection between an artery and
a vein, a so called fistula, provides
such an access point
Haemodialysis access points suffer a high
failure rate and require frequent
interventions and replacement
For some patients it is no longer possible to
create an access point using their own blood
vessels
Use of artificial or donor materials to replace
the blood vessels comes with a high level of
complications and even faster failure rate
Infection is the number one complication for
hemodialysis treatment resulting in high
levels of co-morbidity and mortality
The XS Graft approach has many advantages:
There is no maturation phase and hemodialysis
treatment can start immediately
The blood vessel is body own and there is no rejection
or inflammation as with animal or donor derived
materials
The blood vessel that remains does not contain
artificial materials reducing the risk of infection,
thrombosis and stenosis
Step 1: the XS Graft is surgically inserted in
lower arm, just below the skin
Step 2: a new blood vessel grows around the
XS Graft in just 4 weeks
Step 3: the XS Graft is removed and this
new blood vessel is connected between the
radialis and cephalica to create a
haemodialysis access point
The patient is ready to receive
haemodialysis treatment immediately
The application of the XS Graft is a safe and straightforward procedure, which
can be performed with minimally invasive techniques
0.0s
XS Graft
- Instructions for Use
XS Graft
- Training materials
XS Graft
- Clinical evidence
This section is under review by the Notified Body for conformity with
REGULATION (EU) 2017/745 and will be released in due course
- Experiences biotech leader with
deep tech background and
extensive international experience
Johan van den Arend Schmidt
ceo and cso
- Finance professional with extensive
experience in international
investment banking
Anneke Minnema
- CFO
- Medical doctor with 20+ years
experience as a practicing surgeon
and leading in his field
Dr. Hubert prins
- CMO
Meet the team
- US national with extensive
biotech experience from
multiple companies
ken messier
- coo and ra
- Designed and set up supply
chain with ISO13485
certification
dominik klump
- cto
- Experience Quality Assurance
professional from the biotech
industry
mark ingwersen
- Quality assurance
Viktoria VIgar
- Clinical trial leader
lucie wyatt
- researcher
merel jongmans
- researcher
- Medical doctor, formerly Chief
Medical Officer, B.Braun
Melsungen
- Prof Dr Alexander schachtrupp
- Formerly Director Europe,
Boston Scientific
- Dr Jan Weber
- Medical doctor, Director Monro
hospital, vascular surgeon by
training
- Dr Marjolein de jong
- Medical doctor, chairman
Vascular Access Association US,
Director Brigham Group,
Harvard Medical school
- Dr Dirk Hentschel
- Distinguished professor
biomaterials, Northeastern
University US
- Prof Art J Coury
ADVISORY AND SCIENCE BOARD
- “I recognize the simplicity with
which the Curotis technology
could be used to save patients,
both to create autologous shunts
or to repair existing shunts”
vascular
surgeon
“The options for patients are still
lacking, and Curotis offers an
innovative solution”
interventional
Nephrologist
“I sometimes operate on
children for hours and still the
results are not great”
professor
urology
CLIENT TESTIMONALS
Gaetano Martinolaan 63 – 65
6229 GS Maastricht
- the Netherlands
EUROPEAN ADDRESS
26 Trenton St.
Boston (Charlestown)
- MA 02129 USA
USA ADDRESS
CONTACT